ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
58 announcements with these filters
Dr Reddys Laboratories Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details holdings of promoters, institutions, and public shareholders.
Management discloses a significant manufacturing setback for Semaglutide injection due to out-of-specification impurity levels during scale-up, causing a temporary multi-month supply halt.
Dr. Reddy’s Laboratories disclosed that certain semaglutide batches are out of specification, causing a delay in commercial supplies. The company is investigating the issue.
Dr. Reddy's sent letters to shareholders providing a link to the FY 2025-26 Integrated Annual Report. The notice includes details for the 42nd AGM.
Dr. Reddy's Laboratories notified the 42nd AGM on July 23, 2026. The meeting will be held via video conferencing.
Dr. Reddy's Laboratories has submitted its Integrated Annual Report for FY 2025-26. The report includes corporate overviews, strategic reviews, and statutory reports.
USFDA completed a pre-license inspection at Dr Reddy's Bachupally facility. The company received a Form 483 with seven observations.
Dr. Reddy's launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the U.S. This first-to-market launch strengthens its oncology portfolio and patient access.
Dr. Reddy's Laboratories allotted 12,100 equity shares under its Employee Stock Option Schemes. The allotment increases the company's total paid-up share capital.
Dr. Reddy's Laboratories allotted 12,100 equity shares following the exercise of employee stock options. The shares rank pari-passu with existing equity, slightly increasing the total paid-up capital.
Dr. Reddy's Laboratories filed its FY2026 Annual Report in Form 20-F with the US SEC. The report contains consolidated financial statements prepared under IFRS standards.
Dr. Reddy's Laboratories submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The independent report confirms regulatory compliance with no significant deviations.
Dr. Reddy's senior management will ring the NYSE Closing Bell on May 29, 2026. The ceremony celebrates the company's 25th anniversary of listing on the exchange.
Dr. Reddy's Laboratories launched its generic Semaglutide Injection in Canada following Health Canada approval. This marks the first generic Semaglutide authorization in a G7 country.
Dr. Reddy's Board approved the re-appointment of Dr. K P Krishnan and appointed Mr. Srikanth Velamakanni as Independent Directors. These appointments strengthen corporate governance and leadership.
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹7,546 Cr (-11.5% YoY) and net profit of ₹221.3 Cr (-86.1% YoY) for Q4 FY26.
Dr. Reddy's Laboratories reported FY26 consolidated revenue of ₹33,593.3 Crore and recommended a ₹8 dividend per share. Performance reflects lower generic sales and one-time impact costs.
Dr. Reddy's Laboratories granted 11,92,234 stock options at Rs. 1,293.90 per share, totaling approximately ₹154.21 Crore. Options vest over three years to incentivize employees.
Dr. Reddy's Laboratories received a Notice of Compliance from Health Canada for its generic Semaglutide Injection. This approval authorizes the company to commercialize and distribute the product in Canada, marking a significant milestone in its GLP-1 therapy portfolio. Launch preparations for 2 mg and 4 mg pens are currently underway.
Dr. Reddy's Laboratories clarified that recent trading volume increases are not driven by undisclosed material events. The company separately confirmed it received Drug Identification Numbers from Health Canada for its Semaglutide Injection on April 22, 2026, though final 'Notice of Compliance' approval is still pending.
Dr. Reddy's clarified a news report regarding its Semaglutide Injection. The company confirmed it is awaiting 'Notice of Compliance' from Health Canada but has received 'Drug Identification Numbers' as of April 22, 2026. Management stated there is no material impact on the company from the news article.
Dr. Reddy's Laboratories clarified a news report regarding its Semaglutide Injection. The company confirmed it has not yet received a 'Notice of Compliance' from Health Canada but did receive 'Drug Identification Numbers' (DINs) on April 22, 2026. The company continues to engage with regulatory authorities for Canadian market approval.
Dr. Reddy's Laboratories clarified news reports regarding its Semaglutide Injection. The company confirmed it is still awaiting 'Notice of Compliance' from Health Canada, though it received Drug Identification Numbers on April 22, 2026. Management remains engaged with regulatory authorities to bring the product to the Canadian market.
Dr. Reddy's Laboratories Limited has scheduled a board meeting on May 12, 2026, to consider a final dividend. The trading window for designated persons is closed from March 25, 2026, until May 14, 2026.
Dr. Reddy's Laboratories Ltd has scheduled a Board of Directors meeting to consider recommending a final dividend for the financial year 2025-26. This follows a prior intimation dated March 23, 2026.
Dr. Reddy's Laboratories' Russian subsidiary received a final penalty of ₹1.14 Crore (RUB 9.27 million) from the Russian Tax Authority. The penalty relates to VAT re-classification of marketing services. The company stated this fine has no material impact on its financials or operations.
Dr. Reddy's Laboratories Ltd reported net profit of ₹1,190 Cr (-15.2% YoY) for Q3 FY26.
Dr. Reddy's Laboratories Ltd has entered into an agreement to sell its 100% stake in subsidiary Svaas Wellness Limited for ₹2.23 Crore. The buyer, Enspirit Technology Services Private Limited, is not a related party. The divestment is part of a strategic realignment, as the unit contributed only 0.09% to consolidated turnover.